Risk of developing CMV retinitis following non-ocular CMV end organ disease in AIDS patients

Br J Ophthalmol. 1998 Jul;82(7):748-50. doi: 10.1136/bjo.82.7.748.

Abstract

Aim: To describe the risk of developing cytomegalovirus (CMV) retinitis after a first episode of extraocular CMV disease in AIDS patients.

Methods: A review of the clinical records of 20 AIDS patients, without CMV retinitis, with histologically confirmed extraocular CMV disease, was performed. The main outcome measures were occurrence of CMV retinitis, time to development of CMV retinitis, relation to maintenance therapy, and survival.

Results: A CMV retinitis was diagnosed in 17 of 20 (85%) patients with an immunohistologically confirmed diagnosis of extraocular CMV disease after a mean follow up of 6.4 months. Four patients received maintenance therapy. Three of them developed retinitis after a mean of 9.6 months (range 2-16 months). Sixteen did not receive maintenance and retinitis was diagnosed in 14 of them after a mean of 5.7 months (range 2-11 months). Mean survival was 9.9 months after the diagnosis of extraocular disease, and 4.5 months after the diagnosis of retinitis. In the four patients receiving maintenance therapy, mean survival was 11.5 months, and in the 16 other patients mean survival was 9.5 months. Patients did not receive protease inhibitors.

Conclusion: In the preprotease inhibitor era extraocular CMV disease strongly predisposes to the subsequent development of CMV retinitis. Although maintenance therapy did not prevent the occurrence of retinitis, the time period between both events seems to lengthen considerably. In patients receiving maintenance survival is also longer.

MeSH terms

  • AIDS-Related Opportunistic Infections / complications*
  • Adult
  • Antiviral Agents / therapeutic use
  • Biopsy
  • Cytomegalovirus Infections / complications
  • Cytomegalovirus Infections / drug therapy
  • Cytomegalovirus Infections / pathology
  • Cytomegalovirus Retinitis / complications*
  • Cytomegalovirus Retinitis / drug therapy
  • Cytomegalovirus Retinitis / virology
  • Drug Therapy, Combination
  • Foscarnet / therapeutic use
  • Ganciclovir / therapeutic use
  • Humans
  • Middle Aged
  • Risk Factors

Substances

  • Antiviral Agents
  • Foscarnet
  • Ganciclovir